Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lung Neoplasms × Gemcitabine × Clear all

Phase

Phase 2 88 Phase 3 31 Phase 1 17 Phase 1/2 14 Phase 2/3 3 Phase NA 2 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Extranodal NK-T-Cell 2 Thoracic Neoplasms 1 Squamous Non-small-cell Lung Cancer 1 Oligospermia 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Lung Diseases 1 Fibrosis 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Adenocarcinoma Pancreas 1 Adenocarcinoma 1

Interventions

Propofol 6 Carboplatin 5 Sevoflurane 4 Saline Solution 3 Paclitaxel 3 Nivolumab 3 Erlotinib Hydrochloride 3 Acetaminophen 3 Pemetrexed 2 Midazolam 2 Lidocaine 2 Isoflurane 2 Docetaxel 2 Desflurane 2 Cryotherapy 2 Bupivacaine 2 Bronchoscopy 2 Anesthesia, Inhalation 2 trametinib 1 sotorasib 1 pegfilgrastim 1 icotinib 1 endostar protein 1 durvalumab 1 dabrafenib 1 capmatinib 1 camrelizumab 1 beta Carotene 1 atezolizumab 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡